We are a BioPharma leader focused on helping to address the unmet medical needs of patients with serious diseases.

In 2011, we invested $3.8 billion in the discovery and development of medicines in key areas such as diabetes, oncology, cardiovascular, neuroscience, virology and immunology.

For Adverse Event Reporting please contact 1800 749 749.

Key Products (Ireland)

Brand Name Trade Name
SUSTIVA® (Efavirenz)
BARACLUDE® (Entecavir)
REYATAZ® (Atazanavir sulfate)
SPRYCEL® (Dasatinib)
YERVOY®▼
(Ipilimumab)
ELIQUIS®▼ (Apixaban)
ATRIPLA®
(Tenofovir disoproxil fumarate, Efavirenz, emtricitabine)
OPDIVO® (Nivolumab)
 
 

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Healthcare professionals and patients are asked to report any suspected adverse reactions via Freepost, HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie. Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1800 749 749 or medical.information@bms.com.


Patients - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.



Please go to
http://www.medicines.ie for additional product information

Approval Number: 1506IE1500102-01
Approval Date:
  December 2015